German drugs and pesticides maker Bayer forecast a year without earnings growth for its agricultural products business on Wednesday, as it seeks to complete its $66 billion deal to take over U.S. seeds giant Monsanto. Bayer has said the deal, which would put the size of its agricultural business on a par with its health care unit in terms of revenues, would enable it to develop new combinations of seeds and pesticides to compete against big rivals such as Dow and Dupont, which plan to merge their agricultural businesses.
Article Source:
Reuters